Introduction
============

Immature (or reticulated) platelets (PLTs) contain more RNA than mature PLTs and their number in peripheral blood reflects the rate of thrombopoiesis. Immature PLTs are more active than nonreticulated PLTs because of their higher nucleic acid content and higher expression of P-selectin and glycoprotein. New automated, US Food and Drug Administration-approved methods have been developed to count immature PLTs.[@b1-ott-5-001]--[@b3-ott-5-001] The immature PLT fraction (IPF) count is a useful index of thrombopoiesis, which increases when the IPF rises and decreases when the IPF declines.

The IPF count reflects peripheral PLT destruction that results from the suppression of bone marrow production and can be used as a predictive factor for PLT recovery postchemotherapy myelosuppression or in PLT immunomediated consumption. IPF counts have been described as a better marker of PLT activity not only in thrombopoietic disorders, such as thrombotic thrombocytopenia purpura but also in various clinical conditions, such as hematopoietic stem cell transplantation, myelodysplasia, acute coronary syndrome, and in patients on hemodialysis.[@b4-ott-5-001]--[@b7-ott-5-001]

In this study, we tested the efficacy of transfusions in pediatric patients, who underwent autologous peripheral hematopoietic progenitor cell transplantation, with PLT concentrates (PCs) enriched with young and more active PLTs (IPF). We determined whether this treatment reduced the occurrence of massive or mucosal hemorrhage during the post-transplantation period.

The study design was to evaluate the relationship between two groups of transfusions, one with IPF-poor and the other with IPF-rich solutions stored for the same time and similarly administered in terms of transfusion frequency, and the development of hemorrhagic or transfusion-transmitted complications.[@b8-ott-5-001],[@b9-ott-5-001] We also aimed to verify the utility of a new automated hemoanalyzer to count the IPF in donors and in PCs and to study the outcome in patients.

Materials and methods
=====================

Over a 2-year period, two groups of 20 children (aged 5--18 years) received transfusions with either IPF-poor solutions or with IPF-rich solutions, during autologous peripheral blood stem cell (PBSC) transplantation, according to the EU procedures, [@b33-ott-5-001] as reported in the manual for transfusions at our hospital. In the two groups, the conditioning regimen was the same for the same pathology (hematological pathologies: 14 acute lymphoblastic leukemia, twelve acute myelocytic leukemia (AML), four non-Hodgkin's lymphoma, two Hodgkin's lymphoma, eight solid tumors). Young patients were classified as follows: (1) stable and receiving prophylactic therapy, having a PLT count \< 10,000/μL; (2) having mucosal hemorrhage with a PLT count \< 50,000/μL; (3) exhibiting signs of active bleeding from insertion catheters with a PLT count between 50,000 and 100,000/μL; (4) experiencing massive blood loss with a PLT count of \< 50,000/μL. Before entering this study an informed consent form was delivered to all patients (or their parents), which was approved by the Ethics Committee of the Hospital; only one patient did not return the consent form.

The IPF is donor dependent (range in human blood: 0.3%-- 7.0% of total PLT). The blood donors in our study were selected into two groups, one with an IPF range of 0.3%--3.5%, the other with a range of 3.6%--7.0%. To quantify the reticulated PLTs, we used a new automated instrument, the XE-2100 (Sysmex, Kobe, Japan), with a modern routine, fully automated analyzer and upgraded software.[@b10-ott-5-001] The thrombelastograph (Medival, Padua, Italy) was implemented to aid in the treatment of possible coagulopathy. We used the Procleix Ultrio (Chiron Ltd, Emeryville, CA) test kit-based transcription-mediated amplification for nucleic acid amplification testing studies of serum samples from donors (human immunodeficiency virus, hepatitis C virus, and hepatitis B virus). Otherwise, a microenzyme-linked immunosorbent assay was used in parallel for routine serological screening of anti-human immunodeficiency virus, anti-hepatitis C virus and HBsAg antibodies (Roche, Milan, Italy). For the syphilis test we used a chemiluminescence method (Abbott, Milan, Italy).

The PLT apheresis procedures were performed using healthy volunteer donors according to European regulations. A blood cell separator (Haemonetics MCS Plus version C, Haemonetics Corp, Baintree, MA) was used, with multicomponent collection kits. After collecting standard PLT, the separator was adjusted to collect PLT cyclically. Cycle numbers and volumes were adjusted in the processor to collect an average of 3.0 × 10^11^ (±0.5) PLTs according to the donors' weight and height. Before the plasma reinfusion phase, PLTs harvested were sent to a dry PC bag, withdrawn by a syringe, and counted with the XE-2100 analyzer. The contents of the separation chamber were then driven into the standard PC bag, to avoid plasma contamination, and then into a PC bag containing additive storage solution (T-SOL; Baxter, Deerfield, IL). After collection, both plasma PC and PC with T-SOL were left undisturbed for 1 hour. For sampling, the plasma PC was connected to a 100 mL transfer bag using a sterile connection system and approximately 15 mL was withdrawn for analysis. The other bag contained a mean of 3.0 (±0.2) × 10^11^ PLTs, and was preserved in T-SOL at 23°C for no longer than 2 days to avoid changes of numbers over time.[@b11-ott-5-001] The PCs were leukodepleted by MachoPharma filters (Mouvaux, France) to avoid immunologically mediated effects, further possible bacterial contaminations, and infectious disease transmission (cytomegalovirus, human T-lymphotrophic virus Type I and II).[@b12-ott-5-001]--[@b14-ott-5-001] Finally, they were also treated by a gamma irradiator for 6 minutes, at the time of transfusion.[@b16-ott-5-001],[@b17-ott-5-001] The treatment and checking of the two groups were similar. Physicians and patients understood and approved the treatment with IPF. The data were analyzed using a nonparametric statistical test and the Mann--Whitney test in order to overcome the underlying assumption of normality in parametrics tests with small sample and because the two samples under consideration may not necessarily have the same number of observations. The conditions of the patients were stabilized about the main parameters (stable Hb; normal coagulation tests; general satisfactory health without fever, cough or infections).

Results
=======

In this report only the first two categories, PLT count \< 10,000/μL (prophylactic therapy) and PLT count \< 50,000 (mucosal hemorrhage), were evaluated, for a total number of 40 patients. Twenty received transfusions of 3.0 × 10^11^ PLTs with a low IPF level (0%--1% of total infused PLTs) and the other 20 received IPF-rich transfusions (3%--9% of total infused PLTs). The dose of infused IPF was different, in accordance with the patient's weight: 3.0 (±0.2) for children of 40--60 kg; 1.5 (±0.2) for children of 20--39 kg ([Table 1](#t1-ott-5-001){ref-type="table"}). In this second case, the remaining half dose of IPF was used to prepare heterologous PLT gel to cure skin ulcers, sores, and bone degeneration in other patients.

The data show that the efficacy of transfusion in the 20 patients who received rich IPF was higher than that of low IPF transfusion ([Tables 2](#t2-ott-5-001){ref-type="table"} and [3](#t3-ott-5-001){ref-type="table"}). There was only one case of massive blood loss post-transplantation versus three in the low IPF group and no cases of mucosal hemorrhage. The number of transfusions was lower for patients receiving rich IPF than low IPF solutions and the rich IPF decreased the need for prophylactic transfusions from three to two per week ([Figure 1](#f1-ott-5-001){ref-type="fig"}). The timing of engraftment and patient outcome were the same (mean of 10 days ± 3) for patients receiving autograft transplants, and there were no cases of hemorrhage, bacterial contamination due to management and counting of IPF, transfusion-transmitted infections, or other health-related complications.[@b18-ott-5-001]--[@b23-ott-5-001] We used the Mann--Whitney test to compare the number of transfusions between the two groups of patients and pathologies (because it is a nonparametric statistical test), and a significant difference was observed ([Table 4](#t4-ott-5-001){ref-type="table"}). The initial health conditions before transplantation were similar, including stable hemoglobin values, normal coagulation tests, and general satisfactory health.

Conclusion
==========

The exclusion and inclusion criteria of the study excluded only three cases (fever and cough) and one IPF transfusion (PLT clumps in the bag), as European Bone Marrow Transplantation criteria prescribe for a trial.[@b34-ott-5-001] The processing time to control IPF dosage was relatively short (5 minutes) and did not affect the cost of the procedure. This counting is essential during the last cycle of PLT apheresis, to determine whether the collected plasma has a high percentage of reticulated PLTs for clinical use; if it does not, another cycle is programmed. No viral or bacterial infections due to donors, management of transfusions, or IPF dosage were observed.[@b24-ott-5-001],[@b25-ott-5-001]

In our experience it seems beneficial to use IPF-enriched solutions to transfuse children with complex pathologies, such as during PBSC transplantation, and the IPF transfusions are essential for reducing the incidence of hemorrhagic complications. It is necessary to select blood donors with a high percentage of IPF (3.6%--7.0% of total PLT).

IPF transfusion needs further investigation to establish the social and economic cost, but the benefits of using IPF solutions include reduction in the severity of hematologic disease and related complications, such as intravascular coagulation during PBSC transplantation in children and young patients, and the frequency of minor side effects including mucosal hemorrhage.[@b26-ott-5-001]--[@b29-ott-5-001] The higher cost to carry out "dedicated" PLT apheresis and the purchase of a modern hemocytometer for quantifying the IPF, is offset by the savings in health and medical support for post-transplantation complications. Laboratory and clinical investigations of the functionality of reticulated PLTs in hemostasis, compared to mature PLTs, encouraged these studies.[@b30-ott-5-001]--[@b32-ott-5-001]

It is critical also to choose the dosage and the use of IPF as a prophylactic approach to lower the chances of post-transplantation bleeding, especially in high-risk cases. To collect and determine the dosage of the IPF by PLT apheresis, a standardized procedure is essential. The next step in the refinement of this methodology is the integrated output, which comprises a value that indicates the blood volume of selected donors that must be processed to obtain the desired PLT number and IPF. It involves the creation of a registry of "dedicated" donors.
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###### 

Data for immature platelet fraction-administered concentrates (ABO compatible)

             Total numbers   Whole dose (3 ± 0.2 × 10^11^)   Half dose (1.5 ± 0.2 × 10^11^)
  ---------- --------------- ------------------------------- --------------------------------
  IPF-poor   129             81                              48
  IPF-rich   83              52                              31

**Abbreviation:** ABO, blood groups A, B, AB, and O.

###### 

Use of immature platelet fraction--rich solutions during post-cell transplant period in categories with platelet count \<10,000/μL (prophylactic therapy) and \<50,000/μL (mucosal hemorrhage)

  Patients                 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20
  ------------------------ --- --- --- --- --- --- --- --- --- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Number of transfusions   4   4   4   4   6   4   4   4   4   4    4    5    4    4    4    4    4    4    4    4
  Massive hemorrhages      0   0   0   0   1   0   0   0   0   0    0    0    0    0    0    0    0    0    0    0
  Mucosal hemorrhages      0   0   0   0   0   0   0   0   0   0    0    1    0    0    0    0    0    0    0    0
  Number of infections     0   0   0   0   0   0   0   0   0   0    0    0    0    0    0    0    0    0    0    0

###### 

Use of immature platelet fraction--poor solutions during post-cell transplant period in categories with platelet count \< 10,000/μL (prophylactic therapy) and \<50,000/μL (mucosal hemorrhage)

  Patients                 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20
  ------------------------ --- --- --- --- --- --- --- --- --- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Number of transfusions   6   6   7   6   6   6   8   6   6   7    6    6    6    8    6    6    8    6    6    7
  Massive hemorrhages      0   0   1   0   0   0   1   0   0   0    0    0    0    1    0    0    1    0    0    0
  Mucosal hemorrhages      0   0   1   0   0   0   0   0   0   1    0    0    0    0    0    0    0    0    0    1
  Number of infections     0   0   0   0   0   0   0   0   0   0    0    0    0    0    0    0    0    0    0    0

###### 

Mean of the number of transfusions in the two groups of stem cell transplantations (hematological pathologies: 14 acute lymphoblastic leukemia, twelve acute myelocytic leukemia, four non-Hodgkin's lymphoma, two Hodgkin's lymphoma, eight solid tumors)

  Group      Mean   N    SD      Median   Minimum   Maximum
  ---------- ------ ---- ------- -------- --------- ---------
  Poor IPF   6.45   20   0.759   6        6         8
  Rich IPF   4.15   20   0.489   4        4         6
  Total      5.30   40   1324    6        4         8

**Note:** The Mann--Whitney test shows a significant difference (*P* \< 0.001).

**Abbreviation:** IPF, immature platelet fraction.
